These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 12631365)
1. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365 [TBL] [Abstract][Full Text] [Related]
2. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population. Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912 [TBL] [Abstract][Full Text] [Related]
4. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869 [TBL] [Abstract][Full Text] [Related]
5. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641 [TBL] [Abstract][Full Text] [Related]
6. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024 [TBL] [Abstract][Full Text] [Related]
7. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Abboud H; Coyne D; Smolenski O; Anger M; Lunde N; Qiu P; Hippensteel R; Pradhan RS; Palaparthy RV; Kavanaugh A; Melnick JZ; Williams LA; Batlle D Am J Nephrol; 2006; 26(1):105-14. PubMed ID: 16543714 [TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH; Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404 [TBL] [Abstract][Full Text] [Related]
9. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664 [TBL] [Abstract][Full Text] [Related]
10. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941 [TBL] [Abstract][Full Text] [Related]
11. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients. Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898 [TBL] [Abstract][Full Text] [Related]
12. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Goldenberg MM Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413 [TBL] [Abstract][Full Text] [Related]
13. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Martin KJ; González E; Lindberg JS; Taccetta C; Amdahl M; Malhotra K; Llach F Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S57-63. PubMed ID: 11689389 [TBL] [Abstract][Full Text] [Related]
14. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956 [TBL] [Abstract][Full Text] [Related]
15. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Martin KJ; González EA; Gellens ME; Hamm LL; Abboud H; Lindberg J Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408 [TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
18. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806 [TBL] [Abstract][Full Text] [Related]
19. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. Capuano A; Serio V; Pota A; Memoli B; Andreucci VE J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]